Differentiation induced by the combination of trichostatin A with all-trans retinoic acid in leukemia cells of PLZF-RARα transgenic mice

CHEN Si-Yu,DONG Ying,CHEN Li-Juan,ZHANG Long,WANG Long,CHEN Qiang,WANG Zhen-Yi

DOI: https://doi.org/10.3321/j.issn:1000-2790.2007.16.004

2007-01-01

Abstract:AIM: To investigate the effect of all-trans retinoic acid (ATRA) in combinetion with trichostatin A (TSA), a histone deacetylase inhibitor, on PLZF-RARα-positive cells. METHODS: Molecular cloning technology was used to construct hCG-PLZF-RARα gene. HCG-PLZF-RARα transgenic mice were generated, in which PLZF-RARα fusion gene was driven by hCG promoter to express in myeloid cells of mice. The genotype and phenotype were analyzed by PCR, Southern Blot, RT-PCR, immunofluorescence, morphology of bone marrow cells, peripheral blood cells and spleen cells, pathology of bone, spleen and liver. Bone marrow leukemia cells were cultured in vitro. The change of cell morphology was observed by Wright-Giemsa staining; cell cycle distribution and expression of cell membrane surface differentiation-related antigens (such as CD11b, CD117 and Gr-1) were determined by flow cytometry assay. Expression of PLZF was analyzed by immunofluorescence. Functional differentiation was reflected by nitroblue tetrazolium(NBT) reduction ability. RESULTS:Some hCG-PLZF-RARα transgenic mice developed leukemia resembling human chronic myeloid leukemia. After treated with TSA and RA, bone marrow leukemia cells presented morphologically some features of differentiated cells; the cell growth and proliferation were inhibited in a time-dependent manner. The proportion of cells in S phage was decreased. The expression of PLZF relocated in treated cells. However, no significant difference in NBT assay was documented with the combination therapy. CONCLUSION: Combination of histone deacetylase inhibitor with ATRA can cause a partial differentiation of PLZF-RARα positive cells.